TLDR:
– Regeneron Pharmaceuticals launches Regeneron Ventures with a $500 million commitment to invest in biotech and other technologies.
– The venture arm will be led by Jay Markowitz, M.D., and Michael Aberman, M.D., and will focus on a wide range of therapeutic areas and technologies.
This article discusses the launch of Regeneron Ventures, a new venture arm of Regeneron Pharmaceuticals aimed at investing in biotech and beyond. The company has committed up to $500 million over the next five years for this new private financing arm. Led by Jay Markowitz, M.D., and Michael Aberman, M.D., the venture arm will be agnostic to therapeutic area, technology, and stage of development, including companies beyond drug development such as devices and tools. The goal is to create an ecosystem where the next generation of biotech companies can thrive based on the lessons learned and successes achieved at Regeneron and throughout the executives’ careers.
Regeneron joins other big pharma companies in having a venture capital wing, with firms like Sanofi, Eli Lilly, Bristol Myers Squibb, Astellas, and Novartis also investing in biotech. However, due to biotech’s cold streak in the previous year, some companies had to recalibrate their investment goals. For example, Juergen Eckhardt, M.D., head of Bayer’s VC arm Leaps by Bayer, mentioned that they were not committed to a previous goal of investing 1.3 billion euros through 2024 due to fewer deals being done. Overall, Regeneron Ventures aims to support groundbreaking advancements in science and medicine through its investments.
